Sweden
InSingulo AB is a biotechnology startup based in Sweden, founded in 2017. The company's slogan "The right environment for drug discovery" underscores their focus on providing an optimal setting for drug development. InSingulo specializes in the characterization of drug interactions with complex targets down to the single molecule level. Their biosensing technology allows for drug profiling on membrane proteins embedded in their native environment, enabling drug screening programs against membrane proteins and other challenging therapeutic targets.
The latest milestone for InSingulo AB was the completion of a kr3.80M Seed Round investment on 07 September 2023, with Chalmers Ventures participating as the investor. This injection of capital is expected to fuel the company's efforts in furthering their groundbreaking approach to drug discovery and development.
This recent investment, combined with InSingulo's innovative approach and expertise in the biotechnology and healthcare industries, positions the company for potential growth and impact within the biopharmaceutical landscape. With the backing of Chalmers Ventures, InSingulo AB is poised to advance its mission of facilitating drug discovery in a more effective and targeted manner.
